A Phase 2 interventional study of Acalabrutinib and acalabrutinib and pembrolizumab combination in Ovarian Cancer, sponsored by Acerta Pharma BV. Completed at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing pembrolizumab in Ovarian Neoplasms — 7 open to participants now, 13 under way, 2 of them phase 3. pembrolizumab · Ovarian Neoplasms.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2015, is one of 26 in phase 2, and was the 5th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →7 of the 35 studies testing pembrolizumab in Ovarian Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–75 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Sheba Medical Center · Sites in Israel
Ages 18+ · Women only
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 30 · Phase 3 3
First in 2010; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 38 across the 35 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 31st largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2015, is one of 12 in phase 2, and was the 23rd registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
2 of the studies testing pembrolizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06083844M.D. Anderson Cancer CenterPhase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | 2027-09-30 |
| NCT07261683Obstetrics & Gynecology Hospital of Fudan UniversityPhase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: acalabrutinib monotherapy
Drug: Acalabrutinib
Drug: Combination of acalabrutinib and pembrolizumab
Drug: acalabrutinib and pembrolizumab combination
Also known as: ACP-196
Drug pages: Acalabrutinib · Pembrolizumab
Number of Participants With Overall Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Every 12 weeks for up to 2 years.
| Milestone | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| Started | 39 | 39 |
| Enrolled | 39 | 39 |
| Received study medication | 38 | 39 |
| Discontinued study | 39 | 39 |
| Completed | 0 | 0 |
| Not completed | 39 | 39 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| Participants | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| Number of Participants With Overall Response | 1 | 3 |
Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Acalabrutinib Monotherapy | 16/38 (42.1%) | 8/38 (21.1%) | 34/38 (89.5%) |
| Arm 2 - Acalabrutinib + Pembrolizumab | 22/39 (56.4%) | 16/39 (41%) | 39/39 (100%) |
| Event | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| Small Intestinal ObstructionGastrointestinal disorders | 1/38 | 5/39 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 3/38 | 0/39 |
| Alanine Aminotransferase IncreasedInvestigations | 1/38 | 3/39 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/38 | 3/39 |
| Pericardial EffusionCardiac disorders | 1/38 | 0/39 |
| VomitingGastrointestinal disorders | 1/38 | 0/39 |
| PyrexiaGeneral disorders | 1/38 | 1/39 |
| Non-Cardiac Chest PainGeneral disorders | 1/38 | 0/39 |
| CellulitisInfections and infestations | 1/38 | 0/39 |
| SepsisInfections and infestations | 1/38 | 0/39 |
| Event | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| NauseaGastrointestinal disorders | 16/38 | 29/39 |
| VomitingGastrointestinal disorders | 7/38 | 21/39 |
| HeadacheNervous system disorders | 17/38 | 21/39 |
| FatigueGeneral disorders | 16/38 | 20/39 |
| DiarrheaGastrointestinal disorders | 17/38 | 11/39 |
| Abdominal PainGastrointestinal disorders | 9/38 | 14/39 |
| AnaemiaBlood and lymphatic system disorders | 2/38 | 12/39 |
| Alanine Aminotransferase IncreasedInvestigations | 4/38 | 10/39 |
| Decreased AppetiteMetabolism and nutrition disorders | 9/38 | 10/39 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/38 | 10/39 |
| Age, Continuous(Years) | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Mean | 64.6 ± 11.52 | 64.2 ± 12.75 | 64.4 ± 12.08 |
| Sex: Female, Male(Participants) | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Female | 38 | 39 | 77 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 37 | 36 | 73 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 33 | 34 | 67 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Arm 1 - Acalabrutinib Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| United States | 38 | 39 | 77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Jul 2018, 32 months.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 32 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acalabrutinib · Pembrolizumab